Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Molecular and Cellular Biology|October 16, 2003
PU.1 and pRB interact and cooperate to repress GATA-1 and block erythroid differentiationNatasha Rekhtman, Kevin S Choe, Igor Matushansky, et al.
Cancer Research|October 16, 2003
Reversal of tumorigenicity and the block to differentiation in erythroleukemia cells by GATA-1Kevin S Choe, Farshid Radparvar, Igor Matushansky, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 1, 2012
PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulationElizabeth Charytonowicz, Igor Matushansky, Josep Domingo Doménech, et al.
Human Cell|October 31, 2009
Characterization and comparison of the properties of sarcoma cell lines in vitro and in vivoJoslyn Mills, Tulio Matos, Elizabeth Charytonowicz, et al.
The Journal of Clinical Investigation|February 2, 2012
PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcomaElizabeth Charytonowicz, Melissa Terry, Katherine Coakley, et al.
Annals of the New York Academy of Sciences|November 15, 2006
Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG)Paul A Fitzgerald, Robert E Goldsby, John P Huberty, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 15, 2011
A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimenPrakash Satwani, Monica Bhatia, James H Garvin, et al.
Biorxiv : the Preprint Server for Biology|February 27, 2026
SMARCAL1 is a candidate therapeutic target for ALT-positive tumorsAngelo Taglialatela, Jina Lee, Benura Azeroglu, et al.
Genes & Development|July 14, 2026
SMARCAL1 is a candidate therapeutic target for ALT-positive tumorsAngelo Taglialatela, Jina Lee, Benura Azeroglu, et al.
The Journal of Clinical Investigation|October 20, 2007
Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathwayIgor Matushansky, Eva Hernando, Nicholas D Socci, et al.
Pageof 5